Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France. // The Journal of Prevention of Alzheimer's Disease. – URL: https://www.sciencedirect.com/science/article/pii/S2274580726002062?dgcid=rss_sd_all
Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France. The Journal of Prevention of Alzheimer's Disease. https://www.sciencedirect.com/science/article/pii/S2274580726002062?dgcid=rss_sd_all
“Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France.” The Journal of Prevention of Alzheimer's Disease.
@article{article68271,
title = {Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France},
journal = {The Journal of Prevention of Alzheimer's Disease},
url = {https://www.sciencedirect.com/science/article/pii/S2274580726002062?dgcid=rss_sd_all}
}